Good day, ladies and gentlemen. And welcome to the Fourth Quarter 2015 Oil-Dri Corporation of America Earnings Conference Call. My name is Tony, and I will be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Mr. Dan Jaffee, President and CEO. Please proceed.

Thank you, Tony. And welcome everybody to our fourth quarter and fiscal year end teleconference. Joining me in Chicago is Doug Graham, our Vice President and General Counsel; Dan Smith, our Chief Financial Officer; special guest, Dr. Ron Cravens who runs – he is the President of our Amlan International Animal Health Division, and as always Reagan Culbertson, our Investor Relations Manager, and Reagan, if you’d walk us through the Safe Harbor provision.

Thank you, Dan. Welcome, everyone. On today's call, comments may contain forward-looking statements regarding the company's performance and future periods. Actual results in those periods may materially differ. On our press release and our SEC filings, we highlight a number of important risk factors, trends, and uncertainties that may affect our future performance. We ask that you review and consider those factors in evaluating the company's comments and in evaluating any investment in Oil-Dri stock. Thank you for joining us.

Dan, do you want to cover the financial side?

Sure. Good morning to everyone. Oil-Dri finished the year with a strong fourth quarter reporting earnings per share of $0.71 per diluted share. Sales, however, were down about 1% from the fourth quarter of fiscal 2014. For the full-year, we generated a little over $261 million in sales which were down about 2% from fiscal 2014. Our earnings for the quarter and year reflected an increased net selling price per ton, increased gross profit percentage, lower kiln fuel costs, and lower SG&A. Earnings also reflected the utilization of about $1.7 million of tax attributes. Offsetting some of the positives were increase in non-fuel manufacturing and packaging costs. Our EPS of $1.59 per diluted share for the year was much better than the $1.17 reported in fiscal 2014. It was also the second best year for Oil-Dri trailing only fiscal 2013's record value of $2.07. Our gross profit percentage for the year was 23%, better than the 22% reported in fiscal 2014. In addition to the positive items I have already stated, we also saw lower freight costs due to the decline in the price of diesel fuel. Finally, our earnings in fiscal 2015 were impacted by our tax rate of about 20%, which was lower than 26% reported in fiscal 2014. The FY’15 rate was lower due to the utilization of tax attributes discussed earlier, but we currently believe that our fiscal 2016 tax rate will probably be more in line with our historical norms. Our Retail and Wholesale teams reported lower top line sales value for both the quarter and the year. Sales of branded products were down, but sales of private label cat litter products offset some of that decline. Sales of our industrial products were strong throughout fiscal 2015. The Retail and Wholesale group reported improved earnings…

Dan, thank you. And before we open up the lines for Q&A, I thought it would be good just to have a little back and forth. Ron, thank you for joining us, the Investors requested your presence and you are here. So that is good, you’ve been with us nine years now and when you joined Oil-Dri, we knew we have this unique mineral because we were sort of stumbling our way into a mycotoxin binding application, and why don’t you walk us through the genesis of the sort of the business you’ve inherited and really where we are today and where you see us going.

Thanks Dan. It's a pleasure to be here and I’m happy to kind of go through this. It’s quite a journey if you look at it particularly in retrospect as we’ve gone from basically a generic type product designed or used or marketed for aflatoxin control, which is a single mycotoxin of concern. When I came in, we sat and discussed what we thought perhaps we would like to do and we wanted to expand this business maybe look at other applications and find unique ways to grow value in the business. The basic strategy that was developed at that point is still the one we’re following and that is finding ways to apply the mineral and potentially additives to that mineral that enhance the performance of livestock animals. This is beyond just mycotoxin binding, and we at this point moved forward to cover more than mycotoxins by including indigenously produced bacterial toxins. All of these things basically are the same from the perspective of they cause damage in the digestive system of an animal, that damage results in poor performance or health problems, and we are working to mitigate across a broad spectrum of different toxins in that area. And going forward, we anticipate that we will continue along these lines utilizing other functional additives, which for instance we have just recently started to introduce two new products, NEOPRIME which is targeted primarily for the young swine market and Varium which is targeted for poultry production.

Excellent. And I know there is a general trend globally away from antibiotic solutions in the food chain because if it gets into the food chain then it gets into the humans and then we start to resist the antibiotics when we need them. So talk about how our products fit into that trend?

One of the truly unique features of our products and our approach is that we are targeting a point in the path of genesis of digestive diseases that is not currently being really addressed. Antibiotics work on the bacteria. We target the toxins that the bacteria produce, that cause the damage. So from a pathogenic perspective, our approach and our material is not an antibiotic, and yet it provides the benefit similar to what an antibiotic would do. These are certainly areas where we have done an extensive amount of work. Across the board, we have invested a considerable amount of money in research, and specifically the two products that are coming to market now are the result of three years of additional research on our material. So, we feel very confident that we have – that we understand our mechanism of action. We understand what we are trying to accomplish. We know that we do not compete with antibiotics and we know that we provide benefit to animals similar to that.

Excellent. I think our investors are aware that we have opened up an office in China. You spent a good deal amount of your time there, you built the team. Why don’t you talk us about, what kind of infrastructure we have now in China and what the opportunity potentially is? You know just in generic terms but why China, why did we go to China?

Well, as you have always said you go where the opportunities are. We are in the livestock support industry business and if you want to look just in round numbers, half the swine are produced in China and about a third of the poultry. There is certainly a large population and growing population that is interested in consuming more and more animal protein. So China specifically has the demographics, the economics are improving and certainly the natural animal base for us to work in. All of Asia is actually is similar to that as is Latin America. So they are all growing markets for us. China's specifically we have opened the office. We now just finished our first full year. We are about fully staffed. We have a small office in Shenzhen, China across from Hong Kong. We’ve got five sales people in the field and we have expanded our distribution base from about three or four into the low teens. The basic structure, the basic idea is to take advantage of the distribution systems that exists there through distributors and dealers, as well as targeting larger customers, new integrators that you could potentially sell in the direct manner. This gives us two options on our commercialization efforts. Additionally, we will be registering and launching the new products there as soon as we can, which perhaps is a point that I’d like to make is when we came in, we were not in the food industry for say mentally or from a manufacturing and compliance perspective but we now have all of the standard global requirements in place through our manufacturing and our products. We are in a regulated environment, so we’re limited as far as when and where we can market things based on what we can get approved and yet we’re truly in the human food business because the animals that we sell through or who consume our products ultimately end up in a human food chain.

Excellent. Well, very exciting. There is - we barely gotten any of the oink out of the pig, pun intended we’re really at the beginning of this whole thing and I know we’re very excited for the future growth prospects. I think what we will do is open up the phone line now Tony for Q&A obviously questions on anything the quarter, any of our business units but anything specific to Amlan, Ron I will send over your way.

[Operator Instructions] Your first question comes from the line of Mr. Ethan Starr. Please proceed.

Good morning, great quarter.

Thank you, Ethan.

I am curious what percentage of the private-label scoopable market do you think you have now. And when do you expect the private label lightweight cat litter to really move the needle upwards on Oil-Dri's revenue and earnings?

I know the number, it’s probably - I mean I’m looking at Doug, is he going to let me say the number, I think - when I tell you the number you’re going to be blown away, but there are - this number is going to bounce around depending on which accounts we have at which time and who is out there, but right now I just got this number yesterday. Based on IRI, we have a 90% share. So, the sales that have actually occurred on lightweight private label we’re manufacturing 90% of them. The key is and we’ve also publically disclosed that about 18 percent-ish of the scoopable segment is lightweight now and then roughly 20% of any category in cat litter has gone private label. So, you’re basically talking at the moment, maybe 3.5% of the category would be private label but it is a lagging growth factor, not a leading. Private label is definitely lagging. People get used to it, they enjoy the brand, they enjoy the benefits and then they say, I’d like to save a little money, so I’m going to try the private label. So, it’s not even 3.5% at the moment. It’s probably only about 1%. So, having 90% or 1% is nice, but the real key is, is it going to keep growing and the good news is the lightweight segment is growing dramatically, and so a year from now could add 17%, 18%, be 25%, 30% sure, and now because private label has been out there for over a year, could it be a full 20% probably not that fast, probably if it could be a 10%, let’s say of the 30% now you have a 3% opportunity, Oil-Dri wouldn’t be doing 90% at that point, there will be other competitive things, but if we get hold on to 50% or 60%, I mean you can run the math. So as you’re doing your models, that’s how you would do it.

Okay. But how much of the total private-label scoop market, not just lightweight, what percentage of that?

What percent of Oil-Dri of the total private label scoop?

Yes.

Very small, I think I have reported around 2%.

Okay. And when do you think this might move the needle?

Again, I laid it out for you. You know I don’t give any forward-looking anything. So I just laid it out for you. You just got a -- put your own growth rate and guesses on it, and start running the math. But I mean we obviously have our own internal ones but I’m not going there.

Sure. Okay, thanks. I'll get back in the queue.

Okay. Thanks.

Thank you for your question. Your next question comes from the line of Mr. Robert Earl Smith of Center for Performance Investment. Please proceed.

Well, that was kind of garbled. Good morning and thanks for the numbers in the quarter. So Ron, you mentioned these two new products. California just announced that they have new restrictions on antibiotics. So, what might be the opportunity over the next year to 18 months?

I think the opportunity is very good. The challenge, of course, is that we still are in regulated markets. And so, what we can say and whether we can say things is determined by regulations. The California move is consistent with a number of other changes that are -- that have occurred, I think, across the industry. Most of the poultry industry is voluntarily either removed or are removing antibiotic growth promoters, and all of the pharmaceutical companies have already done so from their -- from the products. So I think the movement is there. I think understanding how and when our product can best fit within the production cycles is going to be key, and then getting some sort of regulatory read or approval that allows us to market inside the US that you are always in a tight spot relative to what is approved and what you can say.

And Ron, it will help our investors. So in the US, you are not allowed to make what, what kind of claims? Certainly we are not allowed to make claims relative to mycotoxin binding. But - which has historically left us out of the market from certainly a promotional perspective. In the new area of antibiotic restriction and then customers looking for alternatives that can help them, we have data that supports that our product would fit. It will come down to what sort of regulatory view the FDA would take, and if in fact, we have to go under an FDA approval process. If that is the case, there is no short-term upside in the US. If we can find some other ways or if there is generated interest, we can potentially gain here. The big opportunity yet is outside of the US where they have a different regulatory environment. Additionally, the antibiotic or the move away from antibiotics is going global. Certainly, market like Brazil, China, some of the large markets that have export business or I guess China really isn't much of an exporter, but they are also in talks and discussions on limiting antibiotics. So, the need for products such as ours is there and increasing, the question will be how can you effectively promote your product in the market to gain that margin.

Would you estimate that you would have an increased growth rate over the 18% that you showed this year, past year in the new fiscal year?

That's always – I'll let Dan give you the…

I will give you the standard answer which is of course we are not going to give any sort of forward guidance. We just sort of paint it out for you and you've got to run your own models.

I was afraid of that. Okay…

But I did learn your middle name is Earl. Did I hear that correctly?

Well, it was incorrect. I don't know how it got that.

All right, so I've got to scratch that off, okay, fine. Thanks, Bob.

Your next question comes from the line of Mr. Ethan Starr. Please proceed.

Yes, what is the CapEx budget for fiscal 2016 and do you plan to continue funding promotional and advertising spending at Q4 levels in fiscal 2016?

We don't disclose our CapEx forward spending and we don't disclose what we are expecting to spend for advertising at this time. So we have not given expectations like that in the past.

Okay. Any chance, I know you don't like to give forward guidance. But any chance the Chinese subsidiary will be profitable in fiscal '6 or even breakeven?

I think what we said is its our hope that somewhere during fiscal '16, for a month, we might reach a breakeven point. I think that is what our past guidance has been.

Okay. Thank you.

Thanks.

Your next question comes from the line of Mr. Robert Smith [Center for Performance Investing]. Please proceed.

So the statement was that you had supplier commitments from over 20 major accounts. So, if you look at those 20 major accounts on a full-year basis, what would that do to sales in the new fiscal year versus the ones that just ended? And how many other major accounts are there so to speak, if you have 20?

Are you talking private-label lightweight?

Yes.

I just wanted to clarify. You know, I really fall back on the comment I made to Ethan. Really, its the function of the growth rate in the adoption. The good news is and look, I've been saying this all along, and I've been saying it to accounts all along, so this is just my opinion. My opinion is 100% of the category is going lightweight. I can't imagine why a consumer if they can get the products they want with the performance they want, would then choose to say, I want a heavier product to carry home. They don't use the product by weight. It has no benefit. Now, at the moment, they can't get exactly what they want, there are trade-offs. So a lot of our competitors are putting fillers in there merely to make a lightweight claim. What they are putting in is nonperforming minerals that are very light in bulk density, which is allowing them to have that claim of this jug only weighs £8, and compare it in size to one that weighs 20. You can put cotton balls in there, you can put air in there, you could have it weigh nothing, and boy, wouldn't that be a great claim, this jug weighs nothing. But meanwhile, it does not absorb, it does not control orders. So they are obviously not going that far, because they get it. But they are diluting the performance of the product. So I can tell you that our private-label lightweights and our branded, everything in there is meant to perform. We are human. We are not going to have perfect product all the time and we're going to have issues and we are dealing with them, sometimes we might have a dust issue or maybe something did not clump…

Dan, you mentioned Target in passing. Is that - have you solicited them? I mean…

I am not - I am taking the fifth. So you can do store checks and if you opened up their private label you'd quickly be able to identify anyone's we are making. If you see all clay in there, then you feel good. If you see recycled newspaper, other sort of filler minerals in there you are going to know it isn't made by Oil-Dri. So that will be your homework assignment, pop into a Target, open up their Boots & Barkley and let me know what you think.

Okay. Thanks.

Your final question comes from the line of Mr. Ethan Starr. Please proceed.

Yes. So of these 20 major accounts you said you got for private-label scoopable, are you doing all their private-label scoopable for these or just some of them you are doing lightweight only or one of the other or what?

It is a blend. A lot of - there are some that we have actually picked up there that are traditional heavy scoopable and do their lightweight. Some we're just doing the lightweight and some are branded partners of ours. So it was easy just to add the lightweight onto them. So its helping both our brand. Its helping our traditional scoop business. Its definitely - I love making sales calls, I always have. But I can tell you, before lightweight it was not a lot of fun for Oil-Dri because we always had to defend why our price per pound was too high, even though the consumer doesn't use it by pound. But that private category was denominated. Now it's the opposite, everyone is going lighter, price per pound is off the table, which is great and its all about performance and attributes, and I love our chances. So anyway, we had - I guess we're pretty much out of time. We had a great quarter. Ron, thank you for joining us and thank you investors who have hung in with the ups and downs. And I read what's out there on the message boards and one of the questions was, is it a trend or a blip? We'll be back to you in 90 days and we will both have a better perspective on that. So, thank you very much and we will be back at you soon. 90 days. Take care.

Ladies and gentlemen, that concludes today's presentation. Thank you for your patience. You may now disconnect and everyone have a great day.